Souzhou Ribo Life Science

Ribo serves a diverse range of clients, including pharmaceutical companies, research institutions, and healthcare providers. The company operates primarily in the Asian market but has a global reach through strategic partnerships and licensing agreements. Ribo's business model is based on a vertically integrated oligonucleotide therapeutic platform that supports the entire lifecycle of RNAi therapeutics, from early-stage research and development (R&D) to commercialization.

The company generates revenue through various channels, including licensing its intellectual property, forming strategic partnerships, and commercializing its RNAi-based products. Ribo has built a significant portfolio of patents and proprietary technologies, which are recognized as industry-leading innovations in RNAi therapeutics.

In summary, Ribo is committed to advancing its RNAi technologies and bringing best-in-class and first-in-class RNAi therapeutics to the market. The company's liver-targeting delivery technology and second-generation modification chemistry have already supported several products entering clinical development phases.